Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Matos MGAD, Chopra Y, Bhat S, Im HJ, Güngör T, Lu M-Y, Stefanelli T, Peyrard S, Smith Y, Sinclair K, Diaz-de-Heredia C. Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial. haematol [Internet]. 2020Sep.10 [cited 2026Mar.25];. Available from: https://haematologica.org/article/view/13170